Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.61 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.61 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.60 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | CDK9 | P50750 | 2/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30676170 | 1.00 | GRM5 (0.61) | GRM5GRM1PDK4PDE10AHTR6 | |
| SCHEMBL17655532 | 0.90 | PDK4 (0.61) | GRM5GRM1PDK4PDE10AHTR6 | |
| SCHEMBL22328949 | 0.87 | GRM5 (0.59) | GRM5GRM1PDK4PDE10AHTR6 | |
| SCHEMBL15951022 | 0.86 | PDK4 (0.60) | GRM5GRM1PDK4PDE10AHTR6 | |
| SCHEMBL16836014 | 0.85 | PDK4 (0.59) | GRM5GRM1PDK4PDE10AHTR6 | |
| SCHEMBL17001926 | 0.85 | PDK4 (0.59) | GRM5GRM1PDK4PDE10AHTR6 | |
| SCHEMBL31040352 | 0.85 | PDK4 (0.59) | GRM5GRM1PDK4PDE10AHTR6 | |
| SCHEMBL30136907 | 0.85 | PDK4 (0.59) | GRM5GRM1PDK4PDE10AHTR6 | |
| Hydrochloric Acid SCHEMBL31025163 | 0.84 | PDK4 (0.58) | GRM5GRM1PDK4PDE10AHTR6 | |
| SCHEMBL19092559 | 0.84 | PDK4 (0.58) | GRM5GRM1PDK4PDE10AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270196-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12331041-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2025-06-17 | — | — | US | disclosed |
| CN-115843271-B | Indole derivatives and their use for the treatment of cancer | 克洛德贝纳尔-里昂第一大学 | 2024-08-13 | — | — | CN | disclosed |
| US-20240132483-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2024-04-25 | — | — | US | disclosed |
| US-11858916-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2024-01-02 | — | — | US | disclosed |
| CN-115843271-A | Indole derivatives and their use for the treatment of cancer | 克洛德贝纳尔-里昂第一大学 | 2023-03-24 | — | — | CN | disclosed |
| EP-3806855-B1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20210332034-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2021-10-28 | — | — | US | disclosed |
| EP-3459953-B1 | NOVEL 5H-PYRROLO[2,3-D]PYRIMIDIN-6(7H)-ONE DERIVATIVE | TAIHO PHARMACEUTICAL CO LTD (JP) | 2021-06-30 | — | — | EP | disclosed |
| US-20190292190-A1 | NOVEL 5H-PYRROLO[2,3-D]PYRIMIDIN-6(7H)-ONE DERIVATIVE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-09-26 | — | — | US | disclosed |
| US-8497265-B2 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8497265-B2 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8497265-B2 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2013-07-30 | — | — | US | disclosed |
| EP-2569306-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | Amgen Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| EP-2569302-A1 | HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS | Amgen, Inc (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20110306591-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | INC., AMGEN | 2011-12-15 | — | — | US | disclosed |
| WO-2011143366-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143495-A1 | HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143366-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143495-A1 | HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331041-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | GRM5 359/4885GRM1 257/4885PDK4 678/4885 |
| US-11858916-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | GRM5 359/4885GRM1 257/4885PDK4 678/4885 |
| US-20110306591-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | PDE10A, PDE9A, HDAC10 | GRM5 719/4885GRM1 1138/4885PDK4 309/4885 |
| US-20240132483-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | GRM5 359/4885GRM1 257/4885PDK4 678/4885 |
| US-20210332034-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | GRM5 359/4885GRM1 257/4885PDK4 678/4885 |
| US-20250270196-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | GRM5 359/4885GRM1 257/4885PDK4 678/4885 |
| US-20190292190-A1 | NOVEL 5H-PYRROLO[2,3-D]PYRIMIDIN-6(7H)-ONE DERIVATIVE | RPS6KA1, RPS6KA3, MAPK9 | GRM5 2705/4885GRM1 1742/4885PDK4 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.